Literature DB >> 22989079

What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?

Ulrich Spandau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22989079     DOI： 10.1111/j.1755-3768.2012.02552.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  7 in total

Review 1.  Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?

Authors:  Andreas Stahl; Ann Hellstrom; Lois E H Smith
Journal:  Neonatology       Date:  2014-10-05       Impact factor: 4.035

2.  Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

Authors:  A Şahin; Z Gürsel-Özkurt; M Şahin; F M Türkcü; A Yıldırım; H Yüksel
Journal:  Ir J Med Sci       Date:  2017-10-07       Impact factor: 1.568

3.  Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.

Authors:  Nada O Taher; Abdullah A Ghaddaf; Sarah A Al-Ghamdi; Jumanah J Homsi; Bandar J Al-Harbi; Lugean K Alomari; Hashem S Almarzouki
Journal:  Front Med (Lausanne)       Date:  2022-05-09

4.  Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.

Authors:  Yingying Chen; Shaoli Wang; Siying Chen; Xingyue Chen; Lizhen Han; Qionglei Zhong; Kaiyan Zhang
Journal:  BMC Ophthalmol       Date:  2022-06-21       Impact factor: 2.086

Review 5.  Aggressive posterior retinopathy of prematurity: a review on current understanding.

Authors:  Devesh Kumawat; Anusha Sachan; Pooja Shah; Rohan Chawla; Parijat Chandra
Journal:  Eye (Lond)       Date:  2021-01-29       Impact factor: 3.775

Review 6.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

7.  Allometric Considerations on Proteins Administered Intravitreally to Children.

Authors:  Thomas Eissing
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-08-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.